

Kevin B Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7513033/publications.pdf>

Version: 2024-02-01

47
papers

14,379
citations

182225

30
h-index

252626

46
g-index

50
all docs

50
docs citations

50
times ranked

16350
citing authors

#	ARTICLE	IF	CITATIONS
1	A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 11-16.	0.7	5
2	Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a phase 3 trial of metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9584-9584.	0.8	1
3	Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2028-2036.e2.	0.3	17
4	Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies. <i>British Journal of Cancer</i> , 2020, 122, 648-657.	2.9	11
5	Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy. <i>JAAD Case Reports</i> , 2018, 4, 13-16.	0.4	13
6	Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study. <i>Cancer Epidemiology</i> , 2018, 57, 80-84.	0.8	7
7	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 503-520.	1.7	9
8	Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. <i>BMC Cancer</i> , 2018, 18, 490.	1.1	73
9	Intraoperative Imaging with a Portable Gamma Camera May Reduce the False-Negative Rate for Melanoma Sentinel Lymph Node Surgery. <i>Annals of Surgical Oncology</i> , 2018, 25, 3326-3333.	0.7	19
10	Clinicopathological features and clinical outcomes associated with TP53 and BRAF ^N mutations in cutaneous melanoma patients. <i>Cancer</i> , 2017, 123, 1372-1381.	2.0	36
11	A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1359-1366.	2.0	29
12	A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. <i>BMC Cancer</i> , 2017, 17, 173.	1.1	12
13	Overall Survival and Durable Responses in Patients With BRAF ^{V600E} Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 871-878.	0.8	266
14	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , 2015, 6, 12809-12821.	0.8	86
15	Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. <i>European Journal of Cancer</i> , 2015, 51, 1435-1443.	1.3	61
16	Intratatumoral talimogene laherparepvec therapy in melanoma. <i>Melanoma Management</i> , 2015, 2, 297-300.	0.1	2
17	Nivolumab in the treatment of advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 945-956.	0.5	0
18	Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. <i>BMC Cancer</i> , 2015, 15, 61.	1.1	25

#	ARTICLE	IF	CITATIONS
19	Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. <i>BMC Cancer</i> , 2015, 15, 400.	1.1	38
20	Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. <i>European Journal of Cancer</i> , 2015, 51, 2689-2697.	1.3	69
21	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.3	138
22	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i> ^{V600} -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3697-3704.	0.8	173
23	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). <i>Clinical Cancer Research</i> , 2014, 20, 4449-4458.	3.2	56
24	Treatment of KIT-mutated metastatic mucosal melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 35.	0.4	18
25	Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3205-3211.	0.8	395
26	Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring <i>BRAF</i> ^{V600E} Mutation. <i>Thyroid</i> , 2013, 23, 1277-1283.	2.4	184
27	MEK Inhibition in the Treatment of Advanced Melanoma. <i>Current Oncology Reports</i> , 2013, 15, 473-482.	1.8	21
28	Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib. <i>Melanoma Research</i> , 2013, 23, 175-178.	0.6	46
29	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2013, 31, 482-489.	0.8	439
30	Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1767-1774.	0.8	335
31	Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. <i>Journal of Clinical Oncology</i> , 2013, 31, 3182-3190.	0.8	530
32	A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. <i>Melanoma Research</i> , 2012, 22, 294-301.	0.6	53
33	Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , 2012, 367, 1694-1703.	13.9	2,445
34	Survival in BRAF V600 ⁺ Mutant Advanced Melanoma Treated with Vemurafenib. <i>New England Journal of Medicine</i> , 2012, 366, 707-714.	13.9	1,955
35	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 782-789.	5.1	479
36	<i>NRAS</i> mutation status is an independent prognostic factor in metastatic melanoma. <i>Cancer</i> , 2012, 118, 4014-4023.	2.0	589

#	ARTICLE	IF	CITATIONS
37	Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naïve metastatic melanoma.. Journal of Clinical Oncology, 2012, 30, 8510-8510.	0.8	41
38	Prognostic factors for survival in melanoma patients with brain metastases. Cancer, 2011, 117, 1687-1696.	2.0	433
39	Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma. Clinical Cancer Research, 2011, 17, 7451-7461.	3.2	115
40	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467, 596-599.	13.7	1,610
41	Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 809-819.	13.9	3,288
42	Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2009, 64, 161-167.	1.1	5
43	A randomized phase III trial of biochemotherapy versus interferon- γ -2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Research, 2009, 19, 42-49.	0.6	37
44	A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer, 2005, 104, 1687-1692.	2.0	57
45	Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer, 2004, 100, 1478-1483.	2.0	92
46	Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer, 2004, 101, 596-603.	2.0	18
47	Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells. Molecular Cancer Therapeutics, 2002, 1, 177-84.	1.9	45